Brachytherapy · 2026
Short course versus conventional interventional radiotherapy (brachytherapy) regimen in locally advanced cervical cancer: A randomized clinical trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Babaie Mohammad, Aghili Mahdi, Poudineh Mohadeseh, Bayani Reyhane, Tagliaferri Luca, Yousefi Ava, Mohammadi Negin, Gomar Marzieh, Garousi Maryam, Jaberi Ramin, Jafari Fatemeh, Macchia Gabriella
Аннотация
PURPOSE: To evaluate whether reducing overall treatment time (OTT) by shortening interventional radiotherapy (IRT; brachytherapy) duration affects outcomes in patients with locally advanced cervical cancer undergoing definitive chemoradiation.
METHODS AND MATERIAL: In this randomized clinical trial, conducted in 2016-2017, 75 patients with stage IB2-IVA cervical cancer were enrolled. The intervention group (n = 41) completed high-dose-rate IRT within 1 week, whereas the control group (n = 34) received the conventional 3-week schedule. The primary endpoint was treatment-related complications.
RESULT: At 5-year follow-up, 7 patients were lost to follow-up, leaving 68 patients for analysis. Median OTT was significantly shorter in the intervention group (59 vs. 64.5 days; p = 0.01), and the complete response rate was higher (53.1% vs. 31.3%; p = 0.041). No significant differences were observed in overall survival (p = 0.962) or disease-free survival (p = 0.128). Multivariate analysis identified treatment response as a significant predictor of survival, with complete response associated with improved outcomes (p < 0.001). Acute and late adverse events, including proctitis, cystitis, and vaginal hemorrhage, were comparable between groups (all p > 0.05).
CONCLUSION: Shortening IRT duration reduced OTT and improved complete response without increasing treatment-related toxicity, although no significant survival benefit was observed.
METHODS AND MATERIAL: In this randomized clinical trial, conducted in 2016-2017, 75 patients with stage IB2-IVA cervical cancer were enrolled. The intervention group (n = 41) completed high-dose-rate IRT within 1 week, whereas the control group (n = 34) received the conventional 3-week schedule. The primary endpoint was treatment-related complications.
RESULT: At 5-year follow-up, 7 patients were lost to follow-up, leaving 68 patients for analysis. Median OTT was significantly shorter in the intervention group (59 vs. 64.5 days; p = 0.01), and the complete response rate was higher (53.1% vs. 31.3%; p = 0.041). No significant differences were observed in overall survival (p = 0.962) or disease-free survival (p = 0.128). Multivariate analysis identified treatment response as a significant predictor of survival, with complete response associated with improved outcomes (p < 0.001). Acute and late adverse events, including proctitis, cystitis, and vaginal hemorrhage, were comparable between groups (all p > 0.05).
CONCLUSION: Shortening IRT duration reduced OTT and improved complete response without increasing treatment-related toxicity, although no significant survival benefit was observed.